Multiple myeloma (MM) is a disorder in which an abnormal clone of plasma cells proliferates in the bone marrow. Plasma cells make antibodies (immune globulins) and in MM a clone of abnormal plasma cells produces large amounts of an abnormal immune globulin-like paraprotein, resulting in a “monoclonal gammopathy.” This paraprotein is found throughout the body and leads to end-organ damage. MM occurs predominantly in older adults with a median age at diagnosis of 70 years. It is twice as common among African Americans than in other racial/ethnic groups. With the growing aging population, the annual incidence of MM is projected to nearly double over the next 20 years.

Clinical Presentation
About 30% of patients with MM are asymptomatic at the time of diagnosis. They are diagnosed incidentally as a result of abnormalities found during routine laboratory testing.

The remainder of patients present with one or more clinical and/or laboratory findings referred to with the acronym “CRAB” which stands for hypercalcemia, Renal failure, Anemia, and Bone abnormalities. Bone abnormalities such as lytic lesions occur in about 90% of MM patients, about one-third of patients with MM are diagnosed after sustaining a pathologic fracture.

Other manifestations of MM may include infections (commonly pneumococcal infections, often related to suppression of normal immunoglobulin production by MM plasma cells in the bone marrow); hyperviscosity-related symptoms (malaise, paresthesia, headaches); and occasionally thrombocytopenia.

Diagnostic Evaluation
Tests used in the evaluation of patients with suspected MM are summarized in the Table 1. Although not all of these tests are essential to establish the diagnosis, test results are useful for disease staging and establishing prognosis.

When interpreting test results, it is important to realize that MM is actually part of a spectrum of monoclonal gammopathies. On one end of the spectrum is monoclonal gammopathy of unknown significance (MGUS). MGUS is a common condition, occurring in 3% of more of older adults. Of patients with MGUS, only about 1% develop overt MM each year.

Further along the spectrum is smoldering multiple myeloma (SMM), which has a much higher progression risk (10% per year). On the far end of the spectrum is MM itself. The criteria used to diagnose MGUS, SMM, and MM are shown in Table 2.

Staging
A new staging system for MM was released in 2015. It is based on lab test results including beta-2 macroglobulin level, cytogenetics, albumin level, and lactate dehydrogenase levels. Staging criteria and 5-year survival rates for each stage are shown in Figure 1.

Table 1. Diagnostic Evaluation for Multiple Myeloma

<table>
<thead>
<tr>
<th>Laboratory studies:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete blood count with differential</td>
</tr>
<tr>
<td>Comprehensive metabolic panel</td>
</tr>
<tr>
<td>Serum protein electrophoresis (SPEP) and immunofixation</td>
</tr>
<tr>
<td>Quantitative immunoglobulin levels (IgG, IgA, IgM)</td>
</tr>
<tr>
<td>Serum free light chain assay</td>
</tr>
<tr>
<td>Serum beta-2 macroglobulin</td>
</tr>
<tr>
<td>Lactate dehydrogenase (LDH)</td>
</tr>
<tr>
<td>Urine protein electrophoresis (UPEP) and immunofixation</td>
</tr>
<tr>
<td>Bone marrow aspirate/biopsy with flow cytometry, cytogenetics, and fluorescent in situ hybridization (FISH)</td>
</tr>
</tbody>
</table>

Imaging:

- Radiographic skeletal survey, whole-body MRI, or whole-body PET/CT scan

TIPS FOR DEALING WITH MULTIPLE MYELOMA (MM) IN OLDER ADULTS

- Use current diagnostic criteria and staging for MM provide more accurate diagnosis and risk stratification.
- Use the IMWG frailty scoring system to help select the optimal therapy based on a patient’s level of fitness to tolerate treatment.
- Collaborative interdisciplinary care is the optimal way to provide care for older adults with MM.
**ELDER CARE**

**Approach to Treatment of MM in Older Adults**

There has been a growing awareness of how frailty can affect treatment tolerance and prognosis in older adults with MM. Studies show that about one-third of patients with MM are frail at the time of diagnosis, but MM therapy has largely been based on studies involving non-frail patients. In 2015, the International Myeloma Working Group (IMWG) developed a frailty scoring system that predicts risks of toxicity and death in older adults with MM. The scoring system categorizes patients into three fitness levels (fit, intermediate fitness, and frail). A calculator for computing the frailty score is at [http://www.myelomafrailtyscorecalculator.net/](http://www.myelomafrailtyscorecalculator.net/).

Using the calculator to categorize patients allows clinicians to better match therapies to a patient's ability to tolerate them. More aggressive therapies with multiple pharmacological agents and autologous peripheral blood stem cell transplantation can be considered for fit patients regardless of age. Conversely, the classification scheme can help avoid complications that might occur if those

<table>
<thead>
<tr>
<th>Table 2. Diagnostic Criteria for MGUS, SMM, and MM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGUS</td>
</tr>
<tr>
<td>SMM</td>
</tr>
<tr>
<td>MM</td>
</tr>
</tbody>
</table>

CRAB events include: hyperCalcemia, Renal failure, Anemia, or Bone abnormalities

**Discontinuing Treatment**

Even though recent advances in treatment have resulted in longer survival times, MM is still an incurable disease. As a result, one challenge is determining when to consider discontinuing treatments aimed at prolonging survival and instead, turning to end-of-life (EOL) care, including hospice care. The decision is not always easy because disease progression in MM is less predictable than with other kinds of cancer.

Although there are no formal consensus guidelines, experts have identified factors that influence when to initiate EOL care in patients with MM. Advanced age with frailty is one factor. For those receiving treatment, factors that suggest the need to discontinue treatment and initiate EOL include treatment-refractory disease, shorter progression-free intervals during treatment, and worsening functional status.

Given the complexity of patient factors and the variety of therapy options, selecting optimal treatment regimens, and knowing if and when to discontinue treatment, requires the expertise of a medical hematologist/oncologist in collaboration with the patient's primary care clinician and other members of an interdisciplinary team.

---

**References and Resources**


**Interprofessional care improves the outcomes of older adults with complex health problems**

Editors: Mindy Fain, MD; Jane Mohler, NP-c, MPH, PhD; and Barry D. Weiss, MD

Interprofessional Associate Editors: Tracy Carroll, PT, CHT, MPH; David Coon, PhD; Teri Kennedy, PhD, MSW, LCSW, ACSW; Jeannie Lee, PharmD, BCP; Marisa Menchola, PhD; Francisco Moreno, MD; Lisa O’Neill, MPH; Floribella Redondo; Laura Vitkus, BA

The University of Arizona, PO Box 245069, Tucson, AZ 85724-5069 | (520) 626-5800 | [http://aging.medicine.arizona.edu](http://aging.medicine.arizona.edu)

Supported by: Donald W. Reynolds Foundation, Arizona Geriatrics Workforce Enhancement Program and the University of Arizona Center on Aging

This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1QHP28721, Arizona Geriatrics Workforce Enhancement Program. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.